CRISPR Therapeutics AG (NASDAQ:CRSP) Position Lifted by Natixis Advisors LLC

Natixis Advisors LLC raised its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 3.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 10,906 shares of the company’s stock after acquiring an additional 400 shares during the quarter. Natixis Advisors LLC’s holdings in CRISPR Therapeutics were worth $589,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in CRSP. New York State Common Retirement Fund bought a new position in CRISPR Therapeutics during the 4th quarter valued at $77,000. Private Advisor Group LLC boosted its stake in CRISPR Therapeutics by 57.9% during the 4th quarter. Private Advisor Group LLC now owns 8,926 shares of the company’s stock valued at $559,000 after acquiring an additional 3,272 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in CRISPR Therapeutics by 2.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 653,023 shares of the company’s stock valued at $40,879,000 after acquiring an additional 15,085 shares during the last quarter. Principal Securities Inc. bought a new position in CRISPR Therapeutics during the 4th quarter valued at $41,000. Finally, Avantax Advisory Services Inc. bought a new position in CRISPR Therapeutics during the 4th quarter valued at $341,000. 69.20% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

CRSP has been the topic of a number of research analyst reports. Barclays reduced their price objective on shares of CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating on the stock in a research note on Tuesday, August 6th. Royal Bank of Canada reduced their price target on shares of CRISPR Therapeutics from $66.00 to $60.00 and set a “sector perform” rating on the stock in a research report on Tuesday, August 6th. Guggenheim restated a “neutral” rating on shares of CRISPR Therapeutics in a research report on Friday, June 28th. Citigroup reduced their price target on shares of CRISPR Therapeutics from $89.00 to $84.00 and set a “buy” rating on the stock in a research report on Thursday, May 23rd. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a research report on Thursday, August 8th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $75.63.

CRISPR Therapeutics Stock Up 1.0 %

CRSP stock opened at $45.89 on Friday. CRISPR Therapeutics AG has a fifty-two week low of $37.55 and a fifty-two week high of $91.10. The firm’s 50-day simple moving average is $51.36 and its 200 day simple moving average is $58.77. The stock has a market cap of $3.90 billion, a PE ratio of -16.87 and a beta of 1.68.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, August 5th. The company reported ($1.49) EPS for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The business had revenue of $0.52 million for the quarter, compared to analysts’ expectations of $12.31 million. The company’s revenue for the quarter was down 99.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.98) earnings per share. Equities analysts forecast that CRISPR Therapeutics AG will post -5.6 EPS for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In other CRISPR Therapeutics news, COO Julianne Bruno sold 3,366 shares of the firm’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the transaction, the chief operating officer now owns 6,745 shares of the company’s stock, valued at approximately $378,327.05. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 4.10% of the stock is owned by corporate insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.